Edition:
United Kingdom

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

12.50USD
25 Sep 2018
Change (% chg)

$0.20 (+1.63%)
Prev Close
$12.30
Open
$12.30
Day's High
$12.75
Day's Low
$12.00
Volume
88,197
Avg. Vol
47,828
52-wk High
$12.75
52-wk Low
$4.90

Latest Key Developments (Source: Significant Developments)

Minerva Neurosciences Inc Files For Mixed Shelf Of Upto $200 Mln
Friday, 10 Aug 2018 

Aug 10 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Minerva Neurosciences Announces Enrollment Of First Patient In Phase 2B Trial Comparing Seltorexant Versus Quetiapine
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2B TRIAL COMPARING SELTOREXANT (MIN-202) VERSUS QUETIAPINE AS ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER.  Full Article

Minerva Neurosciences Screens First Patient In Phase 3 Trial Of Schizophrenia Drug
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA.  Full Article

Minerva Neurosciences Screens First Patient In Phase 3 Trial Of MIN-101 To Treat Negative Symptoms In Schizophrenia
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 3 TRIAL OF MIN-101 TO TREAT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA.MINERVA NEUROSCIENCES INC - ‍ TOP-LINE RESULTS FROM 12-WEEK DOUBLE BLIND PHASE OF TRIAL OF MIN-101 ARE EXPECTED IN FIRST HALF OF 2019​.  Full Article

Minerva Neurosciences names Richard Russell president
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Minerva Neurosciences Inc ::MINERVA NEUROSCIENCES NAMES RICHARD RUSSELL PRESIDENT.MINERVA NEUROSCIENCES INC - REMY LUTHRINGER WILL CONTINUE AS CHIEF EXECUTIVE OFFICER OF MINERVA WHILE RESIGNING HIS POSITION AS PRESIDENT.  Full Article

Minerva Neurosciences reports Q3 loss per share $0.28
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Minerva Neurosciences Inc :Minerva Neurosciences Inc reports third quarter 2017 financial results and business updates.Q3 loss per share $0.28.Q3 earnings per share view $-0.00 -- Thomson Reuters I/B/E/S.Minerva Neurosciences Inc - ‍expects cash, cash equivalents and marketable securities will be sufficient to fund operations for at least next 12 months​.Minerva Neurosciences Inc - ‍cash, cash equivalents, marketable securities as of Sept 30, were about $143.3 million, compared to $83.0 million as of Dec 31, 2016​.  Full Article

Minerva Neurosciences Q3 loss per share $0.24
Thursday, 3 Nov 2016 

Minerva Neurosciences Inc : Minerva Neurosciences - intend to meet with FDA to determine late stage clinical strategy, specifically design of next clinical trials with MIN-101 . Minerva Neurosciences Inc - objective is to initiate trials for min-101 in mid-2017 . Minerva neurosciences reports third quarter 2016 financial results and business updates .Q3 loss per share $0.24.  Full Article

BRIEF-Minerva Neurosciences Q1 Loss Per Share $0.32

* MINERVA NEUROSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATES